Tue, May 13, 8:20 PM (38 days ago)
**Moleculin Biotech, Inc. (MBRX) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** No revenue reported for Q1 2025. - **Operating Expenses:** Total operating expenses were $5.9 million, down from $6.7 million in Q1 2024. - **Research and Development (R&D):** $3.4 million, down from $4.3 million in Q1 2024. - **General and Administrative (G&A):** $2.5 million, up slightly from $2.4 million in Q1 2024. - **Net Loss:** $6.4 million, up from $4.9 million in Q1 2024. - **Cash Flow:** Net cash used in operating activities was $4.6 million, down from $6.7 million in Q1 2024. Net cash provided by financing activities was $8.0 million, primarily from warrant exercises and stock sales. **Profit Margins:** - **Operating Margin:** Negative, with operating losses of $5.9 million. - **Net Margin:** Negative, with a net loss of $6.4 million. **Cash Flow:** - **Operating Cash Flow:** Negative $4.6 million. - **Financing Cash Flow:** Positive $8.0 million, mainly from warrant exercises and stock sales. **Earnings Changes:** - **Earnings per Share (EPS):** Basic and diluted EPS loss was $0.69, compared to $2.02 in Q1 2024. **Quarterly Performance Discussion:** - **Operational Highlights:** Moleculin Biotech is a clinical-stage pharmaceutical company focusing on Annamycin for treating relapsed/refractory acute myeloid leukemia (AML). The company is conducting a pivotal Phase 3 trial (MIRACLE trial) for Annamycin. - **Funding:** The company raised $9.3 million in February 2025 through warrant exercises and stock sales, which improved its liquidity position. - **Clinical Trials:** The MIRACLE trial is progressing, with sites in the US, Europe, and the Middle East/Africa. The company received FDA feedback and guidance, allowing a reduction in the size of Part B of the trial. **Trends and Uncertainties:** - **Financial Trends:** The company continues to operate at a loss, with no revenue generated. Operating expenses have decreased slightly, but the net loss has increased due to changes in fair value of warrant liabilities. - **Uncertainties:** The company faces substantial doubt regarding its ability to continue as a going concern, with cash on hand of $7.7 million as of March 31, 2025, which is not sufficient to fund planned operations for at least one year. The company is seeking additional funding through equity offerings, debt financings, or strategic alliances. **Future Operations Impact:** - **Funding Needs:** The company requires approximately $15 million to support the MIRACLE trial and operations into the first quarter of 2026. - **Strategic Focus:** Moleculin Biotech is focusing on the development of Annamycin and plans to advance other drug candidates through investigator-led studies. **Ticker:** MBRX